| Literature DB >> 32778175 |
Wei Cao1, Junqiang Qiu2, Tianwei Cai1, Longyan Yi1, Dan Benardot3,4, Menghui Zou5.
Abstract
OBJECTIVE: Previous investigations suggest that appropriate nutritional interventions may reduce delayed onset muscle soreness (DOMS). This study examined the effect of D-ribose supplementation on DOMS induced by plyometric exercise.Entities:
Keywords: Isokinetic muscle strength; Muscle damage; Muscle soreness; Oxidative stress
Mesh:
Substances:
Year: 2020 PMID: 32778175 PMCID: PMC7418385 DOI: 10.1186/s12970-020-00371-8
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Subjects’ characteristics for two groupsa
| Group | DRIB | PLAC | Group |
|---|---|---|---|
| N | 11 | 10 | |
| Age (yr.) | 21(2) | 21(2) | 0.448 |
| Height (cm) | 175.36(5.20) | 177.30(2.06) | 0.274 |
| Weight (kg) | 72.6(7.1) | 70.9(9.4) | 0.637 |
| BMI (kg/m2) | 23.6(2.2) | 22.5(2.8) | 0.327 |
| Muscle soreness | |||
| Baseline | 1.5(0.7) | 1.8(0.4) | 0.187 |
| P 24 | 5.4(1.6) | 6.0(1.9) | 0.417 |
| P 48 | 5.3(1.6) | 5.3(2.5) | 0.977 |
DRIB D-ribose group, PLAC Placebo group
aThere was no significant difference between the two groups on these variables
Fig. 1Experimental design
Fig. 2The action essentials of the frog hop. STEP 1: Stand with two hands behind the head and feet shoulder-width apart, squat down, keep the torso upright and the head and chest up. STEP 2: Jump forward, avoid unnecessary high jump. STEP 3: When the feet touch the ground, use the legs to cushion the impact of landing.
Fig. 3Muscle soreness in two plyometric exercise sessions. ** indicates a significant difference vs. Placebo group (p < 0.01). ▲▲indicates a significant difference vs. The first plyometric exercise session (p < 0.01)
Comparison of pre-exercise (mean ± SD) and mean (±95% CI) changes for isokinetic muscle strength markers
| Measure | Pre | Change DRIB | Change PLAC | Group p-value |
|---|---|---|---|---|
| Flexor total work(J) | 496.14(96.82) | |||
| P 24 | 18.67(−72.34, 29.61) | −13.14(−37.36, 69.56) | 0.515 | |
| P 48 | 8.95(− 59.53, 36.26) | − 18.74(− 28.53, 71.93) | 0.557 | |
| Extensor total work(J) | 747.19(162.77) | |||
| P 24 | − 73.46(−2.21, 153.12) | − 146.49(62.84, 225.76)b | 0.281 | |
| P 48 | − 58.1(−18.04, 138.23) | − 117.49(33.36, 197.24)b | 0.372 | |
| Flexor peak torque(N·m) | 104.48(15.90) | |||
| P 24 | 3.71(−11.18, 5.36) | −4.78(− 4.77, 12.57) | 0.323 | |
| P 48 | 3.16(−10.80, 6.07) | −5.68(− 4.05, 13.65) | 0.303 | |
| Extensor peak torque(N·m) | 188.95(38.33) | |||
| P 24 | −19.68(5.66, 39.06)b | −39.35(18.89, 53.91)b | 0.211 | |
| P 48 | −13.41(−2.73, 34.91) | −25.25(2.56, 42.04)a | 0.477 |
DRIB D-ribose group, PLAC Placebo group
a95% CI changes that failed to cross 0 indicates a significant difference vs. Pre
b99% CI changes that failed to cross 0 indicates a significant difference vs. Pre
Comparison of baseline (mean ± SD) and mean (±95% CI) changes for blood related markers
| Measure | Pre | Change DRIB | Change PLAC | Group p-value |
|---|---|---|---|---|
| Creatine kinase(U·L− 1) | 71.52(12.09) | |||
| P 24 | 98.88(− 127.87, −71.90)a | 153.74(− 181.98, − 123.28)a | 0.002c | |
| P 48 | 81.21(− 135.65, − 28.77)a | 138.17(− 193.11, − 81.02)a | 0.079 | |
| Lactate Dehydrogenase(U·L− 1) | 142.18(50.74) | |||
| P 24 | 49.17(−98.68, 5.17) | 114.97 (− 172.08, − 63.16)a | 0.005c | |
| P 48 | 34.01(−73.42, 10.21) | 162.59(− 209.09, − 121.38)a | < 0.001c | |
| Myoglobin (ng·ml− 1) | 46.55(26.85) | |||
| P 24 | 50.66(− 113.81, − 55.37)a | 86.44(− 54.14, − 15.61)a | 0.006c | |
| P 48 | 16.45(− 124.11, −62.82)a | 29.85(−60.99, − 20.58)a | 0.230 | |
| Superoxide dismutase(U·ml− 1) | 48.37(7.57) | |||
| P 24 | 11.91(−17.92, − 4.8)a | 11.6(− 40.12, − 15.25)a | 0.932 | |
| P 48 | 28.23(− 19.09, − 5.32)a | 16.66(−30.3, − 4.22)a | 0.077 | |
| Total antioxidant capacity(U·ml− 1) | 3.59(2.19) | |||
| P 24 | 21.48(−30.16, − 12.06)a | 14.97(−23.49, − 10.48)a | 0.157 | |
| P 48 | 17.36(−24.87, − 5.89)a | 13.11(− 20.34, − 6.7)a | 0.248 | |
| Malondialdehyde(U·ml− 1) | 4.02(1.39) | |||
| P 24 | 1.37(− 3.98, 0.2) | 3.75(−1.33, 0.78)a | 0.029b | |
| P 48 | −0.25(− 5.36, − 0.98) | 2.87(− 3.41, − 1.19)a | < 0.001c |
DRIB D-ribose group, PLAC Placebo group
a99% CI changes that failed to cross 0 indicates a significant difference vs. Pre
bindicates a significant difference vs. Placebo group (p < 0.05)
cindicates a significant difference vs. Placebo group (p < 0.01)